Ukraine will begin to form a supply of an innovative drug for emergency therapy in the case of a nuclear incident. It is an Israeli biotechnological product designed on the basis of placental cells that allows you to save life in cases of acute radiation.
The cooperation agreement was signed by the Israeli company Pluri and the Ukrainian Bank of the Hammothy Cord Blood, reports The Times of Israel . The agreement came into force shortly after the Russian drone attacked the object in the Chernobyl NPP, where the shelter is located above the destroyed reactor.
Pluri specializes in cellular technologies using placental materials. The company creates medicines for the treatment of hematopoietic radiation syndrome, which occurs as a result of high doses of ionizing radiation. This condition leads to the destruction of the bone marrow, hematopoietic system, the immune protection of the body and can become deadly without rapid and effective therapy.
Pluri technology allows you to grow cells outside the mother's body, which opens up opportunities for mass production of such medicines. From now on, together with the Ukrainian partner, the company will start creating a reserve of critical medicines for Ukrainian hospitals, military units and civil protection services.
Full -scale aggression of Russia against Ukraine, constant attacks on the Zaporizhzhya NPP, Chernobyl strikes and repeated threats of the Kremlin to apply nuclear weapons, set a task for Ukraine to create an effective system of response to a possible nuclear catastrophe. The agreement is one of the first steps in this direction.
According to scientists, in the case of a high dose of radiation, death can occur within 4-8 weeks. That is why emergency therapy should be as accessible and prepared in advance.
